Earnings Feed
Start Free
Home/Insiders/Bridger Gary
BG
SEC Insider//CIK 0001600049

Bridger Gary

CIK 00016000494 companiesBOSTON, MA
SEC Profile

Transactions

45

Companies

4

Filings

19

CIK

0001600049

Recent Transactions

45 trades
  • Award
    X4 Pharmaceuticals, Inc$XFOR

    Stock Option (right to buy)

    2026-01-01+110,000→ 0 total
  • Award
    X4 Pharmaceuticals, Inc$XFOR

    Common Stock

    2025-06-09+1,500→ 4,722 total
  • Award
    X4 Pharmaceuticals, Inc$XFOR

    Common Stock

    2024-06-10+45,000→ 96,667 total
  • Award
    X4 Pharmaceuticals, Inc$XFOR

    Common Stock

    2023-06-13+45,000→ 51,667 total
  • Award
    X4 Pharmaceuticals, Inc$XFOR

    Common Stock

    2022-06-06+6,667→ 6,667 total
  • Award
    X4 Pharmaceuticals, Inc$XFOR

    Stock Option (right to buy)

    2021-06-02$9.50/sh+6,000→ 6,000 total
  • Award
    X4 Pharmaceuticals, Inc$XFOR

    Stock Option (right to buy)

    2020-10-05+30,000→ 30,000 total
  • Award
    X4 Pharmaceuticals, Inc$XFOR

    Stock Option (right to buy)

    2020-06-10+3,427→ 3,427 total
  • Award
    X4 Pharmaceuticals, Inc$XFOR

    Stock Option (right to buy)

    2019-03-13+6,854→ 6,854 total
  • Award
    X4 Pharmaceuticals, Inc$XFOR

    Stock Option (right to buy)

    2019-03-13+21,570→ 21,570 total
  • Award
    X4 Pharmaceuticals, Inc$XFOR

    Stock Option (right to buy)

    2019-03-13+21,570→ 21,570 total
  • Award
    Neurogene Inc.$NGNE

    Stock Option (Right to Buy)

    2018-05-07+15,000→ 15,000 total
  • Award
    Neurogene Inc.$NGNE

    Stock Option (Right to Buy)

    2017-05-08+9,000→ 9,000 total
  • Award
    Neurogene Inc.$NGNE

    Stock Option (Right to Buy)

    2016-05-09+7,500→ 7,500 total
  • Other
    ALDER BIOPHARMACEUTICALS INC

    Common Stock

    2015-10-31−3,469,528→ 0 total
  • Other
    Neurogene Inc.$NGNE

    Common Stock

    2015-10-31−1,543,989→ 0 total
  • Award
    ALDER BIOPHARMACEUTICALS INC

    Stock Option (Right to Buy)

    2015-05-19+6,350→ 6,350 total
  • Award
    Neurogene Inc.$NGNE

    Stock Option (Right to Buy)

    2015-03-12+5,000→ 5,000 total
  • Award
    Xenon Pharmaceuticals Inc.$XENE

    Stock Option (Right to Buy)

    2014-11-21+5,144→ 5,144 total
  • Conversion
    Neurogene Inc.$NGNE

    Series A-2 Exchangeable Shares

    2014-03-12−189,393→ 0 total
  • Conversion
    Neurogene Inc.$NGNE

    Series B-1 Exchangeable Shares

    2014-03-12−326,538→ 0 total
  • Conversion
    Neurogene Inc.$NGNE

    Series A-2 Preferred Stock

    2014-03-12−189,393→ 0 total
  • Conversion
    Neurogene Inc.$NGNE

    Series B-1 Preferred Stock

    2014-03-12+326,538→ 0 total
  • Conversion
    Neurogene Inc.$NGNE

    Series B-1 Preferred Stock

    2014-03-12−326,538→ 0 total
  • Conversion
    Neurogene Inc.$NGNE

    Series B-2 Preferred Stock

    2014-03-12−325,035→ 0 total
  • Conversion
    Neurogene Inc.$NGNE

    Series C Preferred Stock

    2014-03-12−378,786→ 0 total
  • Conversion
    Neurogene Inc.$NGNE

    Series A-2 Preferred Stock

    2014-03-12+189,393→ 0 total
  • Disposition to Issuer
    Neurogene Inc.$NGNE

    Common Special Voting Stock

    2014-03-12−40,147→ 0 total
  • Disposition to Issuer
    Neurogene Inc.$NGNE

    Series A-1 Special Voting Stock

    2014-03-12−284,090→ 0 total
  • Disposition to Issuer
    Neurogene Inc.$NGNE

    Series B-1 Special Voting Stock

    2014-03-12−326,538→ 0 total
  • Disposition to Issuer
    Neurogene Inc.$NGNE

    Series C Special Voting Stock

    2014-03-12−378,786→ 0 total
  • Award
    Neurogene Inc.$NGNE

    Common Exchangeable Shares

    2014-03-12$11.00/sh+36,502→ 40,147 total
  • Conversion
    Neurogene Inc.$NGNE

    Series A-1 Exchangeable Shares

    2014-03-12−284,090→ 0 total
  • Disposition to Issuer
    Neurogene Inc.$NGNE

    Series A-2 Special Voting Stock

    2014-03-12−189,393→ 0 total
  • Conversion
    Neurogene Inc.$NGNE

    Series A-1 Preferred Stock

    2014-03-12−284,090→ 0 total
  • Conversion
    Neurogene Inc.$NGNE

    Series B-2 Preferred Stock

    2014-03-12+325,035→ 0 total
  • Conversion
    Neurogene Inc.$NGNE

    Series C Exchangeable Shares

    2014-03-12−378,786→ 0 total
  • Conversion
    Neurogene Inc.$NGNE

    Series B-2 Exchangeable Shares

    2014-03-12−325,035→ 0 total
  • Conversion
    Neurogene Inc.$NGNE

    Series C Preferred Stock

    2014-03-12+378,786→ 0 total
  • Award
    Neurogene Inc.$NGNE

    Common Special Voting Stock

    2014-03-12+36,502→ 40,147 total
  • Disposition to Issuer
    Neurogene Inc.$NGNE

    Series B-2 Special Voting Stock

    2014-03-12−325,035→ 0 total
  • Conversion
    Neurogene Inc.$NGNE

    Common Stock

    2014-03-12+1,543,989→ 1,543,989 total
  • Conversion
    Neurogene Inc.$NGNE

    Common Exchangeable Shares

    2014-03-12−40,147→ 0 total
  • Conversion
    Neurogene Inc.$NGNE

    Series A-1 Preferred Stock

    2014-03-12+284,090→ 0 total
  • Award
    Neurogene Inc.$NGNE

    Stock Option (Right to Buy)

    2014-03-06+8,333→ 8,333 total

Companies

4

Recent Filings

19

Address

C/O X4 PHARMACEUTICALS, INC. 61 NORTH BEACON STREET, 4TH FLOOR

BOSTON, MA, 02134

View on SEC.gov